Hotton Judicael, Beddok Arnaud, Moubtakir Abdenasser, Papathanassiou Dimitri, Morland David
Department of Surgical Oncology, Institut Godinot, 51100 Reims, France.
CReSTIC, UR 3804, Université de Reims Champagne-Ardenne, 51687 Reims, France.
Diagnostics (Basel). 2024 Dec 30;15(1):65. doi: 10.3390/diagnostics15010065.
: Cervical cancer is a significant global health concern, with high incidence and mortality rates, especially in less-developed regions. [F]FDG PET/CT is now indicated at various stages of management, but its analysis is essentially based on SUVmax, a measure of [F]FDG uptake. Radiomics, by extracting a multitude of parameters, promises to improve the diagnostic and prognostic performance of the examination. However, studies remain heterogeneous, both in terms of patient numbers and methods, so a synthesis is needed. : This systematic review was conducted following PRISMA-P guidelines and registered in PROSPERO (CRD42024584123). Eligible studies on PET/CT radiomics in cervical cancer were identified through PubMed and Scopus and assessed for quality using the Radiomics Quality Score (RQS v2.0), with data extraction focusing on study design, population characteristics, radiomic methods, and model performances. : The review identified 22 studies on radiomics in cervical cancer, 19 of which focused specifically on locally advanced cervical cancer (LACC) and assessed various clinical outcomes, such as survival, relapse, treatment response, and lymph node involvement prediction. They reported significant associations between prognostic indicators and radiomic features, indicating the potential of radiomics to improve the predictive accuracy for patient outcomes in LACC; however, the overall quality of the studies was relatively moderate, with a median RQS of 12/36. : While radiomic analysis in cervical cancer presents promising opportunities for survival prediction and personalized care, further well-designed studies are essential to provide stronger evidence for its clinical utility.
宫颈癌是一个重大的全球健康问题,发病率和死亡率都很高,在欠发达地区尤为如此。[F]FDG PET/CT目前在宫颈癌治疗的各个阶段都有应用,但其分析主要基于SUVmax(一种衡量[F]FDG摄取的指标)。放射组学通过提取大量参数,有望提高该检查的诊断和预后性能。然而,在患者数量和方法方面,研究仍然存在异质性,因此需要进行综合分析。
本系统评价按照PRISMA-P指南进行,并在PROSPERO(CRD42024584123)上注册。通过PubMed和Scopus确定了符合条件的关于宫颈癌PET/CT放射组学的研究,并使用放射组学质量评分(RQS v2.0)评估其质量,数据提取重点关注研究设计、人群特征、放射组学方法和模型性能。
该评价确定了22项关于宫颈癌放射组学的研究,其中19项专门针对局部晚期宫颈癌(LACC),并评估了各种临床结局,如生存、复发、治疗反应和淋巴结受累预测。他们报告了预后指标与放射组学特征之间的显著关联,表明放射组学在提高LACC患者预后预测准确性方面的潜力;然而,研究的整体质量相对中等,RQS中位数为12/36。
虽然宫颈癌的放射组学分析在生存预测和个性化医疗方面展现出了有前景的机会,但进一步设计良好的研究对于为其临床应用提供更有力的证据至关重要。